Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes

Key Takeaways Sanofi secured European Commission approval for Teizeild to delay progression to stage 3 T1D disease.SNY-backed TN-10 phase II study showed median progression delayed to 48.4 months vs. 24.4 months with placebo.Teizeild became the first disease-modifying type 1 diabetes therapy authorized in the EU following the nod.Sanofi (SNY) announced that the European Commission has approved Teizeild (teplizumab) to delay the onset of stage 3 type 1 diabetes (T1D) in patients aged eight years and older wi ...